A phase II clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcoma-Reference-Cited by-同舟云学术

A phase II clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcoma

Published:2019-04-23 Issue:6 Volume:8 Page:2994-3003
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Van Tine Brian A.¹^ORCID,Agulnik Mark²,Olson Richard D.³,Walsh Gerald M.³,Klausner Arthur³,Frank Nicole E.⁴,Talley Todd T.⁴,Milhem Mohammed M.⁵

Affiliation:

1. Division of Medical Oncology Washington University in St. Louis St Louis Missouri

2. Division of Hematology/Oncology, Feinberg School of Medicine Northwestern University Chicago Illinois

3. Gem Pharmaceuticals LLC Birmingham Alabama

4. College of Pharmacy Idaho State University Meridian Idaho

5. Division of Hematology/Oncology University of Iowa Hospitals and Clinics Iowa City Iowa

Funder

Gem Pharmaceuticals LLC

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2136

Reference33 articles.

1. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

2. Adriamycin cardiomyopathy—risk factors

3. Phase II evaluation of adriamycin in human neoplasia

4. The Anthracycline Antineoplastic Drugs

5. A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC‐3G3), a human anti‐platelet‐derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS);Tap WD;J Clin Oncol,2015

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anthracycline-induced cardiotoxicity — are we about to clear this hurdle?;European Journal of Cancer;2023-05

2. Role of Nitric Oxide Synthases in Doxorubicin-Induced Cardiomyopathy;Nitric Oxide: From Research to Therapeutics;2023

3. Fatal heart disease in patients with bone and soft tissue sarcoma;Frontiers in Cardiovascular Medicine;2022-10-13

4. Tailoring bismuth-based nanoparticles for enhanced radiosensitivity in cancer therapy;Nanoscale;2022

5. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy;European Journal of Medicinal Chemistry;2021-12